VEGF regulates TRPC6 channels in podocytes

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 921-929

  Thilo, Florian ^a   Liu, Ying ^a,b,c   Loddenkemper, Christoph ^a,d   Schuelein, Ralf ^e   Schmidt, Antje ^f   Yan, Zengcheng ^g   Zhu, Zhiming ^g   Zakrzewicz, Andreas ^a   Gollasch, Maik ^a,h   Tepel, Martin ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c TONGJI UNIVERSITY   (China)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^g THIRD MILITARY MEDICAL UNIVERSITY   (China)

^h Experimental and Clinical Research Center ECRC   (Germany)

Author keywords

Podocytes; Transient receptor potential canonical channel type 6; Vvascular endothelial growth factor

Indexed keywords

CALCIUM ION; CYCLOHEXIMIDE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL ACTIVATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FLUOROMETRY; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CALCIUM; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PODOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRPC CATION CHANNELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84861125416     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr457     Document Type: Article

References (38)

1. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307
2. Kuwahara K, Wang Y, McAnally J et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 2006; 116: 3114-3126
3. Winn MP, Conlon PJ, Lynn KL et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804
4. Möller CC, Wei C, AltintasMMet al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 2007; 18: 29-36
5. Liu Y, Thilo F, Kreutz R et al. Tissue expression of TRPC3 and TRPC6 in hypertensive Munich Wistar Frömter rats showing proteinuria. Am J Nephrol 2010; 31: 36-44
6. Gröne HJ, Simon M, Gröne EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177: 259-267
7. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239
8. Hohenstein B, Hausknecht B, Boehmer K et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69: 1654-1661
9. Liu E, Morimoto M, Kitajima S et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-2104
10. Sung SH, Ziyadeh FN, Wang A et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104
11. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235-246
12. Schiwek D, Endlich N, Holzman L et al. Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. Kidney Int 2004; 66: 91-101
13. Schordan S, Schordan E, Endlich N et al. Alterations of the podocyte proteome in response to high glucose concentrations. Proteomics 2009; 9: 4519-4528
14. Thilo F, Baumunk D, Krause H et al. Transient receptor potential canonical type 3 channels and blood pressure in humans. J Hypertens 2009; 27: 1217-2123
15. Oueslati M, Hermosilla R, Schönenberger E et al. Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides. J Biol Chem 2007; 282: 20676-20685
16. Schmidt A, Wiesner B, Weisshart K et al. Use of Kaede fusions to visualize recycling of G protein-coupled receptors. Traffic 2009; 10: 2-15
17. Dietrich A, Mederos Y Schnitzler M, Gollasch M. Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol 2005; 25: 6980-6989
18. Leuner K, Heiser JH, Derksen S et al. Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators-identification of a novel pharmacophore. Mol Pharmacol 2010; 77: 368-377
19. Blom IE, van Dijk AJ, Wieten L et al. In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 2001; 16: 1139-1148
20. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25-35
21. Leuner K, Kazanski V, Müller M et al. Hyperforin-a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J 2007; 21: 4101-4111
22. Nilius B, Owsianik G, Voets T et al. Transient receptor potential cation channels in disease. Physiol Rev 2007; 87: 165-217
23. Heeringa SF, Möller CC, Du J et al. A novel TRPC6 mutation that causes childhood FSGS. PLoS One 2009; 4: e7771
24. Santín S et al. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2009; 24: 3089-3096
25. Wasada T, Kawahara R, Katsumori K et al. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998; 47: 27-30
26. Santilli F, Spagnoli A, Mohn A et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001; 86: 3871-3876
27. Chou E, Suzuma I, Way KJ et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105: 373-379
28. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020
29. Pocock TM, Foster RR, Bates DO. Evidence of a role for TRPC channels in VEGF-mediated increased vascular permeability in vivo. Am J Physiol Heart Circ Physiol 2004; 286: H1015-H1026
30. Hamdollah Zadeh MA, Glass CA, Magnussen A et al. VEGFmediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation 2008; 15: 605-614
31. Poteser M, Graziani A, Eder P et al. Identification of a rare subset of adipose tissue-resident progenitor cells, which express CD133 and TRPC3 as a VEGF-regulated Ca21 entry channel. FEBS Lett 2008; 582: 2696-2702
32. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41: 773-780
33. Kondo S, Tanaka N, Kubota S et al. Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells. Mol Cancer Ther 2006; 5: 129-137
34. Ramanathan M, Haskó G, Leibovich SJ. Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale. Inflammation 2005; 29: 94-102
35. Kovacs DM, Kaplan BB. Discordant estimates of heterologous promoter activity as determined by reporter gene mRNA levels and enzyme activity. Biochem Biophys Res Commun 1992; 189: 912-918
36. Alvarez-Castelao B, Martín-Guerrero I, García-Orad A et al. Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors. J Biol Chem 2009; 284: 28253-28262
37. Kanellis J, Levidiotis V, Khong T et al. A study of VEGF and its receptors in two rat models of proteinuria. Nephron Physiol 2004; 96: P26-P36
38. Cheng HW, James AF, Foster RR et al. VEGF activates receptoroperated cation channels in human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1768-1776